
NYSEHealthcareMedical - Care Facilities
最新データ
$20.88
+$0.19 · +0.92%
Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a prominent developer, manufacturer, and distributor of a broad range of dialysis products. This portfolio encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, the company produces non-dialysis medical devices, including acute cardiopulmonary and apheresis products. Its pharmaceutical division focuses on developing, acquiring, and in-licensing specialized renal medications, distributing these essential drugs and supplies to both individual patients' homes and dialysis centers. The company also extends its medical offerings to include a variety of specialized services such as vascular, cardiovascular, and endovascular care, operating ambulatory surgery centers for vascular procedures, and providing physician services in nephrology and cardiology. Products are sold directly to dialysis clinics, hospitals, and specialized treatment centers, complemented by sales through local teams, independent distributors, dealers, and agents. By February 23, 2022, Fresenius Medical Care managed an impressive network of 4,171 outpatient dialysis clinics across roughly 150 countries. Established in 1996, the company maintains its headquarters in Bad Homburg, Germany.
終値時点
$20.88
+$0.19 · +0.92%
時間外
$20.88
$0.00 · 0.00%
10月8日 17:47 ET
日中の時刻はETです。市場データは遅延する場合があります。
Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a prominent developer, manufacturer, and distributor of a broad range of dialysis products. This portfolio encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, the company produces non-dialysis medical devices, including acute cardiopulmonary and apheresis products. Its pharmaceutical division focuses on developing, acquiring, and in-licensing specialized renal medications, distributing these essential drugs and supplies to both individual patients' homes and dialysis centers. The company also extends its medical offerings to include a variety of specialized services such as vascular, cardiovascular, and endovascular care, operating ambulatory surgery centers for vascular procedures, and providing physician services in nephrology and cardiology. Products are sold directly to dialysis clinics, hospitals, and specialized treatment centers, complemented by sales through local teams, independent distributors, dealers, and agents. By February 23, 2022, Fresenius Medical Care managed an impressive network of 4,171 outpatient dialysis clinics across roughly 150 countries. Established in 1996, the company maintains its headquarters in Bad Homburg, Germany.
日中レンジ
現在 $20.88
52週レンジ
現在 $20.88
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
買い
バリュエーション
89
大幅な割安
センチメント
48
まちまち
リスク
29
中程度のリスク
モメンタム
43
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a prominent developer, manufacturer, and distributor of a broad range of dialysis products. This portfolio encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, the company produces non-dialysis medical devices, including acute cardiopulmonary and apheresis products. Its pharmaceutical division focuses on developing, acquiring, and in-licensing specialized renal medications, distributing these essential drugs and supplies to both individual patients' homes and dialysis centers. The company also extends its medical offerings to include a variety of specialized services such as vascular, cardiovascular, and endovascular care, operating ambulatory surgery centers for vascular procedures, and providing physician services in nephrology and cardiology. Products are sold directly to dialysis clinics, hospitals, and specialized treatment centers, complemented by sales through local teams, independent distributors, dealers, and agents. By February 23, 2022, Fresenius Medical Care managed an impressive network of 4,171 outpatient dialysis clinics across roughly 150 countries. Established in 1996, the company maintains its headquarters in Bad Homburg, Germany.
日中レンジ
現在 $20.88
52週レンジ
現在 $20.88
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標(EUR) | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 196.28億 EUR | 193.36億 EUR | 194.54億 EUR | 193.98億 EUR | 176.19億 EUR |
| 売上原価 | 145.99億 EUR | 145.79億 EUR | 145.29億 EUR | 145.04億 EUR | 128.46億 EUR |
| 粗利益 | 50.29億 EUR | 47.57億 EUR | 49.25億 EUR | 48.94億 EUR | 47.73億 EUR |
| 研究開発 | 1.58億 EUR | 1.83億 EUR | 2.32億 EUR | 2.29億 EUR | 2.21億 EUR |
| 販売・一般管理 | 30.33億 EUR | 31.43億 EUR | 31.96億 EUR | 31.7億 EUR | 27.73億 EUR |
| 営業費用 | 32.02億 EUR | 32.89億 EUR | 35.56億 EUR | 33.82億 EUR | 29.21億 EUR |
| 受取利息 | 6961.1万 EUR | 7157.5万 EUR | 8821.7万 EUR | 6766.3万 EUR | 7317万 EUR |
| 支払利息 | 3.84億 EUR | 4.07億 EUR | 4.25億 EUR | 3.6億 EUR | 3.54億 EUR |
| 減価償却費と償却費 | 15億 EUR | 17.42億 EUR | 17.52億 EUR | 18.38億 EUR | 16.24億 EUR |
| 営業利益 | 18.27億 EUR | 14.67億 EUR | 13.69億 EUR | 15.12億 EUR | 18.52億 EUR |
| 純利益 | 9.78億 EUR | 5.38億 EUR | 4.99億 EUR | 6.73億 EUR | 9.69億 EUR |
会社概要が更新されました 2026年10月8日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$23.67
上昇余地(13.36%)分割調整後の1株当たりの年間現金分配金。
$0.815
2025年(通年)-2.3% 以来 2021
2026年(一部):$0.8644
$0.8338
2,021
$0.7093
2,022
$0.6181
2,023
$0.6342
2,024
$0.815
2,025
$0.8644
2,026*
* 利用可能な配当履歴のうち、暦年の一部のみを含みます。
| 種別 | 配当落ち日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
配当 | 2026年5月22日 | $0.8644Annual | 2026年5月22日 | 2026年6月8日 |
配当 | 2025年5月23日 | $0.815Annual | 2025年5月23日 | 2025年6月6日 |
配当 | 2024年5月17日 | $0.6342Annual | 2024年5月20日 | 2024年6月3日 |
配当 | 2023年5月17日 | $0.6181Annual | 2023年5月18日 | 2023年6月1日 |
配当 | 2022年5月13日 | $0.7093Annual | 2022年5月16日 | 2022年5月27日 |
配当 | 2021年5月24日 | $0.8338Annual | 2021年5月25日 | 2021年6月7日 |
配当落ち 2026年5月22日
$0.8644
Annual
2026年5月22日基準 · 支払日 2026年6月8日
配当落ち 2025年5月23日
$0.815
Annual
2025年5月23日基準 · 支払日 2025年6月6日
配当落ち 2024年5月17日
$0.6342
Annual
2024年5月20日基準 · 支払日 2024年6月3日
配当落ち 2023年5月17日
$0.6181
Annual
2023年5月18日基準 · 支払日 2023年6月1日
配当落ち 2022年5月13日
$0.7093
Annual
2022年5月16日基準 · 支払日 2022年5月27日
配当落ち 2021年5月24日
$0.8338
Annual
2021年5月25日基準 · 支払日 2021年6月7日
この株式へのエクスポージャーを報告している上場投資信託です。
Pzena U.S. Large Cap Value ETFPZLV240.14万3.50%6900万 USD0.60%$29.70-0.83%
Avantis International Equity ETFAVDE114.82万0.01%190.19億 USD0.23%$89.28-0.22%
iShares Flexible Equity Active ETFBFLX107.4万0.05%21.83億 USD0.40%$25.9369-0.20%
ActivePassive International Equity ETFAPIE64.48万0.06%11.69億 USD0.45%$38.31-0.70%
ETF Series Solutions - AAM Todd International Intrinsic Value ETFTIIV35.2万1.11%3196.74万 USD0.54%$29.83070.00%
ETF Opportunities Trust - Cultivar ETFCVAR30.14万0.68%4434.75万 USD0.87%$30.3277+0.81%
Dimensional - International Core Equity Market ETFDFAI7.27万0.00%177.81億 USD0.18%$41.07-0.19%
Dimensional - International Value ETFDFIV3.07万0.00%213.9億 USD0.27%$55.28+0.13%
Pzena U.S. Large Cap Value ETFPZLV
Avantis International Equity ETFAVDE
iShares Flexible Equity Active ETFBFLX
ActivePassive International Equity ETFAPIE
ETF Series Solutions - AAM Todd International Intrinsic Value ETFTIIV
ETF Opportunities Trust - Cultivar ETFCVAR
Dimensional - International Core Equity Market ETFDFAI
Dimensional - International Value ETFDFIVAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。